Ibio vs Impact Biomedical
Ibio is the larger business, with $100,000 of revenue in fiscal 2026 against $32,000 for Impact Biomedical (3.1 times as much). Impact Biomedical grew faster (-36.0% against -75.0%). Ibio kept more of each dollar of sales as profit: a net margin of -33044.0% against -36993.8%. Ibio carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | IbioIBIO, 2026 | Impact BiomedicalIBO, 2025 |
|---|---|---|
| Revenue | $100,000 | $32,000 |
| Revenue growth | -75.0% | -36.0% |
| Net income | −$33.0m | −$11.8m |
| Operating margin | -35141.0% | -13381.3% |
| Net margin | -33044.0% | -36993.8% |
| Return on equity | -65.7% | -56.5% |
| Free cash flow | −$23.8m | — |
| Cash | $56.4m | $3,000 |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | — |
| Market value | $45.5m | $436m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 4 buys, 0 sales | 0 buys, 6 sales |